Skip to content

Clinical Study for Xu-Ming-Tong-Mai Decoction in the treatment of Acute Ischemic Stroke

Clinical Study for Xu-Ming-Tong-Mai Decoction in the treatment of Acute Ischemic Stroke

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000032680
Enrollment
Unknown
Registered
2020-05-06
Start date
2019-04-01
Completion date
Unknown
Last updated
2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral infarction

Interventions

Sponsors

Chongqing Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. All the patients were diagnosed as ischemic stroke by CT or MRI; 2. The NIHSS scores of patients ranged from 3 to 15(including 3 and 15); 3. Aged 40 to 80 years; 4. The patient's onset is less than 72 hours; 5. The trial was informed consent of the patient or the patient's family or their legal representative and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients who have received or are about to undergo endovascular interventional therapy (including arterial thrombolysis, bridging, mechanical thrombectomy, angioplasty and stenting); 2. Tests confirmed patients with brain trauma, brain tumors, brain parasitosis, and other brain disorders, or with immune system disorders; 3. The score of the modified Rankin scale (Rankin scale) was more than 2; 4. Patients with malignant tumor, CACHEXIA, moderate or severe malnutrition (albumin 80 U/L, The male Serum Creatinine >266 umol /L,The female Serum Creatinine >212 Umol/L); 6. Patients with other effects on limb function and limb function disorders affect the neurological examination; 7. Other diseases or mental disorders that the researchers believe may limit neurologic assessment or affect patient follow-up; 8. Pregnant or lactating women; 9. Patients undergoing clinical trials for other drugs; 10. Patients with contraindications to the drug therapy used in this study.

Design outcomes

Primary

MeasureTime frame
neuron-specific enolase (NSE);Serum S100B;

Countries

China

Contacts

Public ContactTang Jun

Chongqing Traditional Chinese Medicine Hospital

40621694@qq.com+86 13709482548

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026